David Moatazedi
About David Moatazedi
David Moatazedi serves as the President and CEO of Evolus, a position he has held since 2018. With nearly twenty years of experience in the medical aesthetics industry, he has previously held significant roles at Allergan and Novartis Pharmaceuticals.
Work at Evolus
David Moatazedi has served as the President and CEO of Evolus since 2018. Under his leadership, the company has focused on innovation in the medical aesthetics industry. He has been instrumental in driving the company's strategic direction and growth initiatives from its headquarters in Irvine, California.
Previous Experience at Allergan
Prior to his role at Evolus, David Moatazedi held several key positions at Allergan. He served as Senior Vice President of Medical Aesthetics from 2016 to 2018. His earlier roles included Vice President of Sales and Marketing for US Plastic Surgery and Senior Director of Marketing for both Dermal Fillers and US Plastic Surgery. He played a significant role in the launch of various products and was involved in multi-billion-dollar acquisitions during his tenure.
Education and Expertise
David Moatazedi earned his MBA from Pepperdine Graziadio Business School in 2004. He also holds a degree in Chemistry from California State University, Long Beach, which he completed in 2000. His educational background supports his nearly twenty years of experience in the medical aesthetics industry, where he has built market-leading brands.
Background in Pharmaceuticals
Before joining Allergan, David Moatazedi worked at Novartis Pharmaceuticals. He held the position of District Manager from 2002 to 2005 and worked as a Sales Consultant from 2000 to 2002. His experience in pharmaceuticals laid the foundation for his later success in the medical aesthetics field.
Family and Residence
David Moatazedi resides in Newport Beach, California, with his wife and three children. His family life is an important aspect of his personal background, complementing his professional achievements in the medical aesthetics industry.